Ipsen S.A. (IPSEY)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Ipsen S.A. (IPSEY) trades at $43.09 with AI Score 52/100 (Hold). Ipsen S. A. is a global biopharmaceutical company focused on specialty care medicines in oncology, neuroscience, and rare diseases. Market cap: 57B, Sector: Healthcare.
Last analyzed: Mar 15, 2026Ipsen S.A. (IPSEY) Healthcare & Pipeline Overview
Ipsen S.A. is a global biopharmaceutical company specializing in oncology, neuroscience, and rare diseases, with a diverse portfolio including Somatuline and Dysport. Operating in a competitive pharmaceutical landscape, Ipsen focuses on developing and commercializing innovative therapies, maintaining a significant presence in specialty care markets and a growing emphasis on medical aesthetics.
Investment Thesis
Ipsen S.A. presents a compelling investment thesis based on its focus on specialty care medicines and a diversified portfolio of products. The company's key value drivers include the continued growth of its oncology and neuroscience franchises, particularly Somatuline and Dysport. With a profit margin of 12.1% and a gross margin of 70.6%, Ipsen demonstrates strong profitability. Upcoming catalysts include potential regulatory approvals for new indications and expansion into new geographic markets. However, investors should be aware of potential risks, including competition from generic drugs and the uncertainty of clinical trial outcomes. The company's beta of 0.34 suggests lower volatility compared to the overall market.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $58.04 billion reflects Ipsen's significant presence in the biopharmaceutical industry.
- P/E ratio of 28.23 indicates investor expectations for future earnings growth.
- Gross margin of 70.6% demonstrates strong pricing power and efficient cost management.
- Dividend yield of 0.92% provides a modest income stream for investors.
- Beta of 0.34 suggests lower volatility compared to the broader market, making it a potentially stable investment.
Competitors & Peers
Strengths
- Diversified product portfolio in specialty care.
- Strong presence in oncology and neuroscience.
- Global distribution network.
- Established partnerships with other pharmaceutical companies.
Weaknesses
- Reliance on key products for revenue generation.
- Exposure to generic competition.
- High research and development costs.
- Dependence on regulatory approvals.
Catalysts
- Ongoing: Continued growth of Somatuline sales for neuroendocrine tumors and acromegaly.
- Ongoing: Expansion of Dysport into new aesthetic indications.
- Upcoming: Potential regulatory approvals for new therapies in oncology and neuroscience.
- Upcoming: Strategic acquisitions to expand product portfolio.
- Ongoing: Geographic expansion in emerging markets.
Risks
- Ongoing: Increasing competition from generic drug manufacturers.
- Potential: Uncertainty of clinical trial outcomes.
- Potential: Changes in healthcare regulations.
- Potential: Economic downturns affecting healthcare spending.
- Ongoing: Currency risk due to fluctuations in exchange rates.
Growth Opportunities
- Expansion of Dysport into new aesthetic indications: The global medical aesthetics market is projected to reach $25 billion by 2028, driven by increasing demand for non-invasive cosmetic procedures. Ipsen can leverage its existing Dysport franchise to capture a larger share of this market by developing new aesthetic indications and expanding its marketing efforts. This expansion could significantly boost revenue and profitability within the next 3-5 years.
- Geographic expansion in emerging markets: Emerging markets, such as China and India, offer significant growth opportunities for Ipsen due to their large populations and increasing healthcare spending. By establishing a stronger presence in these markets, Ipsen can diversify its revenue streams and tap into new customer bases. This expansion could involve strategic partnerships, acquisitions, or organic growth initiatives and is expected to yield results within the next 5-7 years.
- Development of novel oncology therapies: Oncology remains a key focus area for Ipsen, with significant unmet medical needs and a growing market. By investing in research and development of novel oncology therapies, Ipsen can strengthen its pipeline and launch innovative products that address these needs. This includes exploring targeted therapies, immunotherapies, and other cutting-edge approaches. Success in this area could lead to substantial revenue growth over the next 5-10 years.
- Strategic acquisitions to expand product portfolio: Ipsen can pursue strategic acquisitions to expand its product portfolio and gain access to new therapeutic areas or technologies. This could involve acquiring companies with complementary products, strong research pipelines, or established market presence. Such acquisitions can accelerate Ipsen's growth and diversification efforts, providing long-term value creation.
- Leveraging digital health technologies: The integration of digital health technologies, such as telemedicine and remote patient monitoring, presents a significant opportunity for Ipsen to improve patient outcomes and enhance its competitive advantage. By developing and implementing digital health solutions, Ipsen can personalize treatment plans, improve adherence, and gather valuable data to inform its research and development efforts. This integration is expected to drive efficiency and improve patient care within the next 3-5 years.
Opportunities
- Expansion into new geographic markets.
- Development of novel therapies for unmet medical needs.
- Strategic acquisitions to expand product portfolio.
- Leveraging digital health technologies.
Threats
- Increasing competition from generic drug manufacturers.
- Uncertainty of clinical trial outcomes.
- Changes in healthcare regulations.
- Economic downturns affecting healthcare spending.
Competitive Advantages
- Strong intellectual property protection for its key products.
- Established relationships with healthcare providers and payers.
- Specialized expertise in oncology, neuroscience, and rare diseases.
- Global distribution network.
About IPSEY
Founded in 1929 and headquartered in Boulogne-Billancourt, France, Ipsen S.A. has evolved into a global biopharmaceutical company with a focus on specialty care. The company's portfolio includes innovative medicines in oncology, neuroscience, and rare diseases. Key products include Somatuline, used in the treatment of neuroendocrine tumors and acromegaly, and Dysport, a botulinum toxin used for motor muscular disorders and medical aesthetics. Ipsen also offers Decapeptyl for advanced metastatic prostate cancer, Cabometyx for renal cell and second-line hepatocellular carcinoma, and Onivyde for second-line metastatic pancreatic cancer. Additionally, Ipsen provides treatments for growth failure in children, such as NutropinAq and Increlex, and various consumer healthcare products in the gastro-intestinal area, including Smecta and Forlax. Ipsen has established collaborations with companies like Debiopharm, Exelixis, and Galderma to expand its product offerings and market reach. With a presence in numerous countries, Ipsen continues to focus on developing and commercializing innovative therapies to address unmet medical needs.
What They Do
- Develops and commercializes pharmaceutical products.
- Focuses on specialty care medicines in oncology.
- Offers treatments for neuroscience-related disorders.
- Provides therapies for rare diseases.
- Markets drugs for gastroenterological conditions.
- Offers products for cognitive disorders.
- Provides medical aesthetic treatments.
Business Model
- Develops and patents innovative pharmaceutical products.
- Commercializes and markets these products globally.
- Generates revenue through product sales.
- Collaborates with other companies to expand product offerings and market reach.
Industry Context
Ipsen S.A. operates in the competitive specialty pharmaceutical industry, which is characterized by high research and development costs, stringent regulatory requirements, and intense competition from both established players and generic drug manufacturers. The global pharmaceutical market is expected to continue growing, driven by an aging population, increasing prevalence of chronic diseases, and advancements in medical technology. Ipsen's focus on oncology, neuroscience, and rare diseases positions it to capitalize on these trends. Competitors include companies like Chiesi Farmaceutici S.p.A. (CHALF) and Daiichi Sankyo Co. (DSKYF).
Key Customers
- Patients with cancer.
- Individuals with neurological disorders.
- Patients with rare diseases.
- Individuals seeking medical aesthetic treatments.
Financials
Chart & Info
Ipsen S.A. (IPSEY) stock price: $43.09 (+1.53, +4.07%)
Latest News
-
Ipsen showcases transformative potential of early immuno-oncology pipeline at AACR
Yahoo! Finance: IPSEY News · Mar 18, 2026
-
Ipsen - February 2026 - Monthly information relative to the total number of voting rights and shares composing the share capital
Yahoo! Finance: IPSEY News · Mar 13, 2026
-
Why ORIC Pharmaceuticals (ORIC) Is Down 15.1% After Ipsen Pulls Tazverik Over Safety Concerns
Yahoo! Finance: IPSEY News · Mar 13, 2026
-
Ipsen appoints Michelle C. Werner as EVP, President of North America
Yahoo! Finance: IPSEY News · Mar 12, 2026
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for IPSEY.
Price Targets
Wall Street price target analysis for IPSEY.
MoonshotScore
What does this score mean?
The MoonshotScore rates IPSEY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
Ipsen showcases transformative potential of early immuno-oncology pipeline at AACR
Ipsen - February 2026 - Monthly information relative to the total number of voting rights and shares composing the share capital
Why ORIC Pharmaceuticals (ORIC) Is Down 15.1% After Ipsen Pulls Tazverik Over Safety Concerns
Ipsen appoints Michelle C. Werner as EVP, President of North America
Leadership: David Loew
CEO
David Loew is the Chief Executive Officer of Ipsen. He has extensive experience in the pharmaceutical industry, having held various leadership positions at Sanofi, including Executive Vice President and Head of Sanofi Pasteur, the company's vaccines division. Prior to Sanofi, he worked at Roche for 20 years in various roles. His experience spans commercial operations, strategic planning, and product development. He holds a degree in Economics from the University of St. Gallen.
Track Record: Since becoming CEO of Ipsen, David Loew has focused on strengthening the company's pipeline, expanding its presence in key markets, and driving innovation in its core therapeutic areas. Key milestones under his leadership include strategic acquisitions and partnerships to enhance Ipsen's product portfolio and accelerate growth. He has also emphasized the importance of digital transformation and leveraging technology to improve patient outcomes.
Ipsen S.A. ADR Information Unsponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. IPSEY functions as a Level 1 ADR, meaning it trades over-the-counter (OTC) without requiring the same level of regulatory compliance as listed stocks. This allows U.S. investors to invest in Ipsen S.A. without directly dealing with foreign exchanges.
- Home Market Ticker: Euronext Paris (IPSE), France
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: IPSE
IPSEY OTC Market Information
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market. Companies in this tier often have limited financial disclosure and may not meet the listing requirements of major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries higher risks due to the lack of regulatory oversight and transparency compared to listed companies. This tier is also known as the Pink Open Market.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure.
- Lower trading volume and liquidity.
- Wider bid-ask spreads.
- Increased price volatility.
- Potential for fraud or manipulation.
- Verify the company's registration and legal status.
- Obtain and review available financial statements.
- Assess the company's business model and competitive landscape.
- Research the company's management team and track record.
- Evaluate the company's risk factors and potential liabilities.
- Consult with a financial advisor or legal professional.
- Understand the OTC market and its associated risks.
- Established presence in the biopharmaceutical industry.
- Diversified product portfolio.
- Partnerships with reputable companies.
- Positive analyst ratings (if available).
- History of regulatory approvals for its products.
IPSEY Healthcare Stock FAQ
What does Ipsen S.A. do?
Ipsen S.A. is a global biopharmaceutical company focused on developing and commercializing innovative medicines in three key therapeutic areas: oncology, neuroscience, and rare diseases. Its portfolio includes established brands like Somatuline for neuroendocrine tumors and Dysport for motor muscular disorders and medical aesthetics, alongside a pipeline of new therapies aimed at addressing unmet medical needs. The company operates worldwide, partnering with other pharmaceutical companies to expand its reach and product offerings.
What do analysts say about IPSEY stock?
Analyst consensus on IPSEY stock is mixed, reflecting the inherent uncertainties in the pharmaceutical industry. Key valuation metrics, such as the P/E ratio of 28.23, suggest investor expectations for future earnings growth. Growth considerations include the potential for new product approvals and expansion into emerging markets. However, analysts also highlight risks such as competition from generic drugs and the uncertainty of clinical trial outcomes. Investors should conduct their own due diligence and consider their individual risk tolerance before investing.
What are the main risks for IPSEY?
The main risks for Ipsen S.A. include increasing competition from generic drug manufacturers, which could erode sales of its established products. The uncertainty of clinical trial outcomes poses a risk to its pipeline of new therapies. Changes in healthcare regulations and economic downturns affecting healthcare spending could also negatively impact the company's financial performance. Additionally, as an ADR, IPSEY is subject to currency risk due to fluctuations in exchange rates.
What are the key factors to evaluate for IPSEY?
Ipsen S.A. (IPSEY) currently holds an AI score of 52/100, indicating moderate score. The stock trades at a P/E of 29.2x, near the S&P 500 average (~20-25x). Key strength: Diversified product portfolio in specialty care.. Primary risk to monitor: Ongoing: Increasing competition from generic drug manufacturers.. This is not financial advice.
How frequently does IPSEY data refresh on this page?
IPSEY prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven IPSEY's recent stock price performance?
Recent price movement in Ipsen S.A. (IPSEY) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Diversified product portfolio in specialty care.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider IPSEY overvalued or undervalued right now?
Determining whether Ipsen S.A. (IPSEY) is overvalued or undervalued requires examining multiple metrics. Its P/E ratio is 29.2. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying IPSEY?
Before investing in Ipsen S.A. (IPSEY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be limited or inconsistent.